Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation

Tumor suppressor genes and their effector pathways have been identified for many dominantly heritable cancers, enabling efforts to intervene early in the course of disease. Our approach on the subject of early intervention was to investigate gene expression patterns of morphologically normal one-hit cells before they become hemizygous or homozygous for the inherited mutant gene which is usually required for tumor formation. Here, we studied histologically non-transformed renal epithelial cells from patients with inherited disorders that predispose to renal tumors, including von Hippel-Lindau (VHL) disease and Tuberous Sclerosis (TSC). As controls, we studied histologically normal cells from non-cancerous renal epithelium of patients with sporadic clear cell renal cell carcinoma (ccRCC). Gene expression analyses of VHLmut/wt or TSC1/2mut/wt versus wild-type (WT) cells revealed transcriptomic alterations previously implicated in the transition to precancerous renal lesions. For example, the gene expression changes in VHLmut/wt cells were consistent with activation of the hypoxia response, associated, in part, with the Warburg effect. Knockdown of any remaining VHL mRNA using shRNA induced secondary expression changes, such as activation of NF?B and interferon pathways, that are fundamentally important in the development of RCC. We posit that this is a general pattern of hereditary cancer predisposition, wherein haploinsufficiency for VHL or TSC1/2, or potentially other tumor susceptibility genes, is sufficient to promote development of early lesions, while cancer results from inactivation of the remaining normal allele. The gene expression changes identified here are related to the metabolic basis of renal cancer and may constitute suitable targets for early intervention.

[1]  R. Nussbaum,et al.  Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2014, The American journal of surgical pathology.

[2]  D. Kwiatkowski,et al.  Sun exposure causes somatic second-hit mutations and angiofibroma development in tuberous sclerosis complex. , 2014, Human molecular genetics.

[3]  E. Aronica,et al.  Fetal brain mTOR signaling activation in tuberous sclerosis complex. , 2014, Cerebral cortex.

[4]  A. Knudson,et al.  Meta-Analysis Identifies NF-κB as a Therapeutic Target in Renal Cancer , 2013, PloS one.

[5]  L. Kopelovich,et al.  Heritable one-hit events defining cancer prevention? , 2013, Cell cycle.

[6]  W. Kaelin,et al.  The VHL/HIF axis in clear cell renal carcinoma. , 2013, Seminars in cancer biology.

[7]  L. Cantley,et al.  Breathless cancer cells get fat on glutamine , 2012, Cell Research.

[8]  K. Rantanen,et al.  Prolyl Hydroxylase PHD3 Enhances the Hypoxic Survival and G1 to S Transition of Carcinoma Cells , 2011, PloS one.

[9]  Jiannis Ragoussis,et al.  High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. , 2011, Blood.

[10]  H. Friess,et al.  PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer , 2010, British Journal of Cancer.

[11]  Peter H. Baenziger,et al.  A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers , 2010, Oncotarget.

[12]  B. Brüne,et al.  High glucose concentrations attenuate hypoxia-inducible factor-1alpha expression and signaling in non-tumor cells. , 2010, Experimental cell research.

[13]  Karthik Devarajan,et al.  Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations , 2010, Cancer Prevention Research.

[14]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[15]  W. Rathmell,et al.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo , 2009, Oncogene.

[16]  W. Kaelin The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[17]  Bhavinkumar B. Patel,et al.  One-hit effects in cancer: altered proteome of morphologically normal colon crypts in familial adenomatous polyposis. , 2008, Cancer research.

[18]  Margit Rosner,et al.  The mTOR pathway and its role in human genetic diseases. , 2008, Mutation research.

[19]  K. Devarajan,et al.  Comparison of RNA amplification methods and chip platforms for microarray analysis of samples processed by laser capture microdissection , 2008, Journal of cellular biochemistry.

[20]  B. Ebert,et al.  pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. , 2007, Molecular cell.

[21]  Robert Gentleman,et al.  Using GOstats to test gene lists for GO term association , 2007, Bioinform..

[22]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[23]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[24]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[25]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[26]  L. del Peso,et al.  Identification of a functional hypoxia-responsive element that regulates the expression of the egl nine homologue 3 (egln3/phd3) gene. , 2005, The Biochemical journal.

[27]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[28]  A. Knudson,et al.  Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations , 2004, Cancer biology & therapy.

[29]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[30]  L. del Peso,et al.  The von Hippel Lindau/Hypoxia-inducible Factor (HIF) Pathway Regulates the Transcription of the HIF-Proline Hydroxylase Genes in Response to Low Oxygen* , 2003, Journal of Biological Chemistry.

[31]  Alfonso Bellacosa,et al.  Genetic hits and mutation rate in colorectal tumorigenesis: Versatility of Knudson's theory and implications for cancer prevention , 2003, Genes, chromosomes & cancer.

[32]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[33]  A. Knudson,et al.  National Cancer Institute Workshop Report: the phakomatoses revisited. , 2000, Journal of the National Cancer Institute.

[34]  J. Licht,et al.  WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts , 1999, Oncogene.

[35]  E. Henske,et al.  Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. , 1998, Cancer research.

[36]  R. Snell,et al.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. , 1998, Human molecular genetics.

[37]  O. Yoshida,et al.  Transcript levels of aquaporin 1 and carbonic anhydrase IV as predictive indicators for prognosis of renal cell carcinoma patients after nephrectomy , 1998, International journal of cancer.

[38]  W. Risau,et al.  Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.

[39]  B. Ponder,et al.  Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. , 1997, Human molecular genetics.

[40]  M. Bertagnolli,et al.  Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. , 1996, Cancer research.

[41]  A. Webster,et al.  Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. , 1996, Journal of medical genetics.

[42]  W. Linehan,et al.  Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. , 1995, The Journal of urology.

[43]  A. Rustgi Hereditary gastrointestinal polyposis and nonpolyposis syndromes. , 1994, The New England journal of medicine.

[44]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[45]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[46]  Yu Wang,et al.  A glycolytic mechanism regulating an angiogenic switch in prostate cancer. , 2007, Cancer research.

[47]  W. Linehan,et al.  Germline mutations in the Von Hippel‐Lindau disease (VHL) gene in families from North America, Europe, and Japan , 1996, Human mutation.

[48]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .